ONKOLOGIE / Onkologie. 2023;17(4):233-240 / www.onkologiecs.cz 240 HLAVNÍ TÉMA Možnosti a opodstatněnost znovunasazení anti-EGFR léčby u předléčených RAS wild pokročilých kolorektálních karcinomů nie s primární profylaxí G-CSF, kožní toxicita (typická akneformní vyrážka 3. stupně a tato byla příčinou od 18. cyklu léčby k redukci cetuximabu. Jinak ale infusion-related reakce nenastaly, neobjevila se nauzea, průjem, anémie. Tato salvage terapie prodloužila za velmi dobré kvality života pacienta léčebnou periodu o více než rok! A bezesporu byla důvodem i toho nejdůležitějšího, co pacienta zajímá – a to délky jeho života. A zde k tomuto uvedená rechallenge anti-EGFR léčba bezesporu přispěla! LITERATURA 1. Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17(10):1426-1434. 2. Schwartzberg LS, Rivera F, de Valdecilla M, et al. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. J Clin Oncol. 2014;32(21):2240-2255. 3. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, palceno-controlled, phase 3 trial. Lancet Lond Engl. 2013;381:303-312. 4. Mayer RJ, Van Cutsem E, Falcon A, et al. Radomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl Med. 2015;372:1909-1919. 5. Cremolini C, Rossini D, Dall´Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistence to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2018;343-350. 6. Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastaic colorectal cancer patients: how to come away from aquired resistence? Ann Oncol Off Eur Soc Med Oncol. 2012;23:2313-2318. 7. Tsuji A, Nakamura M, Watanbe T, et al. P-243 Phase II of third- -line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy. Ann Oncol. 2018:29. 8. Osawa H, Shinozaki E, Nakamur M, et al. P-481 Phase II study of cetuximab rechallenge in patients with ras wild- -type metastatic colorectal cancer: E-rechallenge trial. Ann Oncol. 2018:29. 9. Siena S, George P, Gerald P, et al. Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect of outcomes. Ann Oncol. 2017:28. 10. Tanioka H, Asanlo M, Yoshida R, et al. Cetuximab re-treatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study. Oncol Lett. 2018;16:3674-3680. 11. Stein A, Binder M, Goekkurt E, et al. Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). Gastrointestinal Cancer Symposium 2020. J Clin Oncol. 2020;36:15 Suppl. 12. Martinelli E, Ciardiello D, Martini G, et al. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: Challenges and future perspectives. Ann Oncol. 2020;31:30-40. 13. Troiani T, Martinelli E, Ciardiello D, et al. Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon. Gastrointestinal Cancer Symposium 2019. J Clin Oncol. 2019; 37:4 Suppl. 14. Pietrantonio F, Perrone F, Biondani P, et al. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab -based regimens: Clinical oucome and biomarkers of efficacy. Cancer Biol Ther. 2013;14:1098-1103. 15. Wasan H, Meade AM, Adams R, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014;15:631-639. 16. Kaechele V, von Wichert G, Adler G, et al. Response to reintroduction of cetuximab in 5 patients with advanced, chemotherapy-resistant, colorectal cancer without progressive disease following first-line therapy with cetuximab-containing regimen. Oncology. 2008;74:1236-6. 17. Metges J, Raoul J, Achour N, et al. PANERB study: Panitumumab after cetuximab-based regimen failure. J Clin Oncol. 2010;28:el:4000. 18. Marino A, Caliolo C, Sponziello F, et al. Panitumumab after progression on cetuximab in KRAS wild-type metastaric colorectal cancer patients: a sisngle institution experience. Tumori. 2015;101:524-528. 19. Kiss I, Mlcochova J, Bortlicek Z, et al. Efficacy and toxicity of panitumumab after progression on cetuximab and predictive value of MiR-31-5p in metastatic wild- -type KRAS colorectal cancer patients. Anticancer Res. 2016;36:4955-4959. 20. Fora AA, McMahon JA, Wilding G, et al. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan. Oncology. 2013;84:210-213. 21. Feng Q, Wei Y, Ren L, et al. Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study. Oncotarget. 2016;7:1380-1396. 22. Ciardiello F, Normanno N, Martinelli E, et al. Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab. Ann Oncol. 2015;26:iv120-121. 23. Vladimirova LY, Abramova NA, Kit OI. Treatment for RAS wild-type (wt) metastatic colorectal cancer (mCRC): continuation of anti-EGFR therapy while switching chemotherapy regimen. ASCO 2016; Abstract 744. 24. Available from: https://ascopubs.org/doi/abs/10.1200/ JCO.2021.39.15_suppl.3506. 25. Available from: www.clinicaltrials.gov/ct2/show/ NCT03227926. 26. Available from: www.clinicaltrials.gov/ct2/show/ NCT02934529. 27. Available from: www.clinicaltrials.gov/ct2/show/ NCT03311750. 28. Available from: www.clinicaltrials.gov/ct2/show/ NCT03524820. 29. Available from: www.clinicaltrials.gov/ct2/show/ NCT03087071. 30. Available from: www.clinicaltrials.gov/ct2/show/ NCT02316496. 31. Available from: https://ascopubs.org/doi/abs/10.1200/ JCO.2021.39.3_suppl.TPS143. VĚRNÝM ČTENÁŘŮM SUPPLEMENTUM Imunoterapie vstoupila do 1. linie léčby zhoubných nádorů jícnu, gastroezofageální junkce a žaludku MUDr. Ondřej Kubeček, Ph.D., MUDr. Peter Grell, Ph.D. www.solen.cz | www.onkologiecs.cz Suppl. A | 2023 | ISBN 978-80-7471-465-8 Imunoterapie vstoupila do 1. linie léčby zhoubných nádorů jícnu, gastroezofageální junkce a žaludku MUDr. Ondřej Kubeček, Ph.D., MUDr. Peter Grell, Ph.D.
RkJQdWJsaXNoZXIy NDA4Mjc=